心血管疾患モデルにおける内皮機能不全の新規阻害剤としてのアーク・シェル由来ペプチドAWLNH (P3) とPHDL (P4)
Chathuri Kaushalya Marasinghe1, Lakshi Ayoda Dayarathne1, Jae-Young Je2
1Department of Food and Life Science, Pukyong National University, Busan 48513, Republic of Korea.
Tissue & cell
|September 3, 2025
まとめ
アークシェルペプチドP3とP4は,酸化されたLDLによって引き起こされる内皮機能不全から保護します. これらの生物活性ペプチドは 細胞の健康を改善し 炎症を軽減することで 血管疾患の治療に有望です
科学分野:
- 生物化学
- 分子生物学
- 心血管研究
背景:
- 内皮機能不全は 動脈硬化や心血管疾患の 重要な早期指標です
- 酸化低密度脂質 (oxLDL) は,内皮機能障害の開始に重要な役割を果たします.
- 内皮機能不全と闘うための効果的な治療戦略の開発は,血管の健康にとって極めて重要です.
研究 の 目的:
- オックスLDL誘発の内皮機能障害に対するアーク・シェル系ペプチドAWLNH (P3) とPHDL (P4) の保護効果を調査する.
- P3 と P4 の細胞活力,窒素酸化物産生,およびヒト静脈内皮細胞 (HUVEC) の主要な分子マーカーの影響を評価する.
- oxLDLチャレンジの文脈でP3とP4の抗酸化,抗アポプトシス,および抗炎症特性を評価する.
主な方法:
- 酸素化された低密度脂質 (oxLDL) に暴露されたヒト静脈内皮細胞 (HUVEC) を利用した.
- 細胞活性の評価,酸化窒素 (NO) 濃度,内皮酸化窒素合成酵素 (eNOS) の発現
- レクチン様酸化低密度リポプロテイン受容体-1 (LOX-1) 表現,活性酸素種 (ROS) レベル,および脂質過酸化を測定した.
- 抗酸化酵素活性,アポトーシス関連タンパク質 (バックス/Bcl-2比),ミトコンドリア膜ポテンシャル,炎症マーカー (ICAM-1,VCAM-1) を分析した.
主要な成果:
- P3とP4は,HUVECの生存能力と窒素酸化物の生成を著しく高め,eNOSの発現を向上させました.
- ペプチドは,oxLDL誘発のLOX-1発現を抑制し,ROSと脂質過酸化を減少させることで強力な抗酸化効果を示した.
- P3とP4は,oxLDL誘発のアポトーシスを抑制し,ICAM- 1とVCAM- 1をダウン調節することによって血管炎症を緩和した.
- アークシェルペプチドはミトコンドリア膜の潜在能力を効果的に保存した.
結論:
- アーク・シェル由来ペプチドP3とP4は,HUVECにおけるoxLDL誘発の内皮機能不全を効果的に改善する.
- これらのペプチドは,重要な抗酸化,抗アポプトシス,および抗炎症作用を示す.
- P3とP4は,血管疾患の治療のための新しい生物活性ペプチドベースの治療薬として潜在的に持っています.
関連する概念動画
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
673
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
673